Nicolina Capoluongo

Oct 20, 2023 | mdpi.com | Nicolina Capoluongo |Annamaria Mascolo |Francesca Bernardi |Marina Sarno

1. IntroductionAntiviral therapies, when used alone, have been reported to not always be sufficient to change the course of the COronaVIrus Disease 2019 (COVID-19) [], especially in frail patients. Therefore, identifying new therapeutic options to prevent or fight this disease in its early phase is essential []. Tixagevimab–cilgavimab is a long-acting monoclonal antibody combination of two Fc-modified human monoclonal antibodies obtained from patients who recovered from COVID-19.

Oct 10, 2023 | mdpi.com | Francesca Bernardi |Annamaria Mascolo |Marina Sarno |Nicolina Capoluongo

1. IntroductionThe rapid development of coronavirus disease 2019 (COVID-19) vaccines has helped change the course of the pandemic by reducing illness severity and hospital admissions [1]. As of January 2023, the European Medicines Agency (EMA) had granted authorization to seven COVID-19 vaccines [2]. Among these, two are mRNA vaccines: BNT162b2 mRNA (produced by Pfizer-BioNTech, approved on 21 December 2020) and mRNA-1273 (Moderna, approved on 6 January 2021).